Open access
Open access
Powered by Google Translator Translator

Heart Failure/Transplantation

AHA Scientific Statement | Complementary and alternative medicines in the management of heart failure.

9 Dec, 2022 | 13:40h | UTC

Complementary and Alternative Medicines in the Management of Heart Failure: A Scientific Statement From the American Heart Association – Circulation

News Release: Some benefits, potential risks with alternative medicines for heart failure – American Heart Association

 


ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison.

8 Dec, 2022 | 12:57h | UTC

ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison – ESC Heart Failure

Original Guidelines:

#ACC22 – 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.

#ESCCongress – 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure – SGLT2 inhibitors are now recommended for patients with heart failure with reduced ejection fraction regardless of the presence of diabetes.

 


Review | How to assess systemic venous congestion with point of care ultrasound.

6 Dec, 2022 | 13:37h | UTC

How to assess systemic venous congestion with point of care ultrasound – European Heart Journal – Cardiovascular Imaging

 


SR | Methamphetamine-associated heart failure.

5 Dec, 2022 | 00:06h | UTC

Methamphetamine-associated heart failure: a systematic review of observational studies – Heart

Editorial: Too much heterogeneity: envisioning a new approach to methamphetamine associated heart failure – Heart

News Release: Prevalence of ‘meth’ heart failure now in wide range of social class and racial groups – BMJ Newsroom

Commentaries: Prevalence of Methamphetamine-Related Heart Failure Increasing – HealthDay

 


Fluid volume homeostasis in heart failure: a tale of 2 circulations.

5 Dec, 2022 | 00:00h | UTC

Fluid Volume Homeostasis in Heart Failure: A Tale of 2 Circulations – Journal of the American Heart Association

 


M-A | Risk of hypovolemia associated with sodium–glucose cotransporter-2 inhibitors treatment.

2 Dec, 2022 | 14:31h | UTC

Risk of hypovolemia associated with sodium–glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials – Frontiers in Cardiovascular Medicine

 


Epidemiology of heart failure in young adults: a French nationwide cohort study.

2 Dec, 2022 | 14:19h | UTC

Epidemiology of heart failure in young adults: a French nationwide cohort study – European Heart Journal

 


M-A | Sodium restriction in patients with heart failure.

1 Dec, 2022 | 14:08h | UTC

Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials – Circulation: Heart Failure (link to abstract – $ for full-text)

Commentary: Sodium Restriction No Help, No Harm in HF, Meta-analysis Confirms – TCTMD

 

Commentary on Twitter

 


2ry analysis of a RCT | Decongestion with acetazolamide in acute heart failure across the spectrum of left ventricular EF.

25 Nov, 2022 | 12:45h | UTC

Decongestion with Acetazolamide in Acute Decompensated Heart Failure across the Spectrum of Left Ventricular Ejection Fraction: a Pre-specified Analysis from the ADVOR trial – Circulation

Original Study: RCT | Acetazolamide resulted in faster decongestion in patients with acute decompensated heart failure with volume overload.

 

Commentary on Twitter

 


RCT | Impact of empagliflozin on decongestion in acute heart failure.

23 Nov, 2022 | 14:04h | UTC

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial – European Heart Journal

Commentary: Empagliflozin in Patients Hospitalized for Acute Heart Failure – EMPULSE – American College of Cardiology

 

Commentary on Twitter

 

Under a https://creativecommons.org/licenses/by-nc/4.0/ license

 


Cohort Study | Prognostic prediction of genotype vs. phenotype in genetic cardiomyopathies.

23 Nov, 2022 | 13:57h | UTC

Prognostic Prediction of Genotype vs Phenotype in Genetic Cardiomyopathies – Journal of the American College of Cardiology

 

Commentary on Twitter

 

Under a Creative Commons license

 


Right heart failure in the ED: approach to diagnosis and management.

23 Nov, 2022 | 13:54h | UTC

Right Heart Failure in the ED: Approach to Diagnosis and Management – emDocs

 


RCT | Influenza vaccine to reduce adverse vascular events in patients with heart failure.

18 Nov, 2022 | 13:26h | UTC

Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial – The Lancet Global Health

Commentary: 

Flu vaccines cut pneumonia, cardiovascular issues in heart failure patients – CIDRAP

Flu Shot Could Be Lifesaver for Folks With Heart Failure – HealthDay

 


M-A | Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction.

18 Nov, 2022 | 13:14h | UTC

Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials – Cardiovascular Diabetology

 


RCT | Early routine use of ECMO fails to improve outcomes in patients with cardiogenic shock.

11 Nov, 2022 | 14:01h | UTC

Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial – Circulation

Commentaries:

Early use of ECMO devices to support adults with cardiogenic shock did not improve clinical outcomes – News Medical/American Heart Association

Early ECMO No Better Than Watch-and-Wait Approach in Cardiogenic Shock – TCTMD

Immediate Use of ECMO Did Not Improve Outcomes in Patients with Cardiogenic Shock – HCP Live

 

Commentary on Twitter

 


RCT | Using an algorithm to stratify the risk of patients with acute heart failure may improve outcomes.

9 Nov, 2022 | 12:30h | UTC

Trial of an Intervention to Improve Acute Heart Failure Outcomes – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: New Tool Assesses Risk in Acute HF Then Suggests Next Steps, Cutting Later Events – TCTMD

 

Commentary on Twitter

 


RCT | Rapid up-titration of guideline-directed medical therapies for acute heart failure reduced readmissions and deaths.

8 Nov, 2022 | 12:24h | UTC

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial – The Lancet (free registration required)

News Release: Maximizing heart failure meds within 2 weeks reduced risk of hospital readmission, death – American Heart Association

Commentary: STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends – TCTMD

 


Review | Management of heart failure with reduced ejection fraction.

8 Nov, 2022 | 12:17h | UTC

Management of heart failure with reduced ejection fraction – Heart

 


RCT | In patients with CKD (eGFR 20-45 mL/min per 1.73 m2), Empagliflozin reduced the risk of progression of kidney disease.

7 Nov, 2022 | 12:56h | UTC

Empagliflozin in Patients with Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: EMPA-KIDNEY supports SGLT2 inhibition for chronic kidney disease – medwire News

Video Summary: EMPA-KIDNEY results: Empagliflozin reduces kidney disease progression and cardiovascular deaths

 

Commentary on Twitter

 


RCT | Intravenous iron did not significantly reduce hospital admissions in patients with heart failure and iron deficiency.

7 Nov, 2022 | 12:48h | UTC

Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial – The Lancet

Commentaries:

Effectiveness of Intravenous Iron Treatment Versus Standard Care in Patients With Heart Failure and Iron Deficiency – IRONMAN – American College of Cardiology

IRONMAN Misses but Lends Support to IV Iron Repletion in HF – TCTMD

 


Review | Optimal perfusion targets in cardiogenic shock.

31 Oct, 2022 | 13:45h | UTC

Optimal Perfusion Targets in Cardiogenic Shock – JACC: Advances

 

Commentary on Twitter

 


Evolving presentation of cardiogenic shock: a review of the medical literature and current practices.

31 Oct, 2022 | 13:46h | UTC

Evolving Presentation of Cardiogenic Shock: A Review of the Medical Literature and Current Practices – Cardiology and Therapy

 

Commentary on Twitter

 


Cohort Study | Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation.

31 Oct, 2022 | 13:42h | UTC

Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation – European Heart Journal

 

Commentary on Twitter

Under a https://creativecommons.org/licenses/by-nc/4.0/ license

 


Study commentary | From the management of altitude sickness to congestion in acute HF: a new season for acetazolamide?

27 Oct, 2022 | 12:27h | UTC

From the management of altitude sickness to treatment of congestion in acute heart failure: a new season for acetazolamide? – European Heart Journal (free for a limited period)

Original study: RCT | Acetazolamide resulted in faster decongestion in patients with acute decompensated heart failure with volume overload.

 


Diaphragmatic function in cardiovascular disease: JACC review topic of the week.

25 Oct, 2022 | 13:22h | UTC

Diaphragmatic Function in Cardiovascular Disease: JACC Review Topic of the Week – Journal of the American College of Cardiology

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.